PURPOSE Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. MATERIALS AND METHODS We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. RESULTS The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. CONCLUSION Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.

中文翻译：

---

帕唑帕尼治疗转移性软组织肉瘤：多中心回顾性研究。

目的软组织肉瘤与预后不良和化学治疗效率低有关。Pazopanib是一种口服可利用的多酪氨酸激酶抑制剂，已在患有非脂肪细胞性晚期软组织肉瘤的患者中进行了研究。这项回顾性研究的目的是评估土耳其人口中单药帕唑帕尼对软组织肉瘤的疗效和安全性的现实生活数据。材料与方法我们回顾性分析了土耳其八个中心地区共103例接受帕唑帕尼治疗的晚期非脂肪细胞性软组织肉瘤的患者（41例男性，62例女性）。帕唑帕尼的剂量为每天800毫克。分析了无进展生存期，总生存期和不良事件。结果中位年龄为50岁（范围38-58）。多数患者患有平滑肌肉瘤（41％）。中位无进展生存期为4.3个月，中位总体生存期为10.1个月。主要的常见毒性是疲劳，厌食，体重减轻，恶心，高血压，≥3级毒性是疲劳，厌食，体重减轻和肝病。结论帕唑帕尼是一种有效且可耐受的药物，在表现良好状态的复发，晚期非脂肪细胞性软组织肉瘤患者中具有良好的耐受性。